All News
Filter News
Found 806,261 articles
-
Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16
1/8/2020
The conference will take place January 13-16, 2020, at the Westin St. Francis Hotel in San Francisco.
-
Transcenta Holding Secures $100 Million Series B Plus Financing
1/8/2020
Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 million USD series B+ round.
-
Adagene Completes $69 Million Series D Financing Led by Growth Investor General AtlanticProceeds will support advancement of lead immunotherapy clinical programs and extend the frontiers of novel technology
1/8/2020
Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced the completion of a $69 million Series D financing, including $50 million from lead investor General Atlantic.
-
GHR Healthcare Acquires HIM Division of HCTec
1/8/2020
Tampa-Based Revenue Cycle Improvement Group Expands GHR Family of Brands
-
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
1/8/2020
NorthSea Therapeutics B.V. announced the closing of a US $40 million Series B financing round.
-
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
1/8/2020
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference.
-
Intercept to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2020 at 10:00 a.m. Pacific Time.
-
Tauriga Sciences, Inc. Confirms Plans to Commence the Development of a Pharmaceutical Grade Version of Tauri-Gum
1/8/2020
Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the“Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced plans to commence development of a pharmaceutical grade version of Tauri-Gum™
-
Pelican BioThermal Releases an Update to its SaaS Asset Management Software, Crēdo ProEnvision™
1/8/2020
New version advances smart management of temperature-controlled shipments and sets the foundation for future IoT integration
-
Esteve acquires German proprietary, specialty, hospital-focused company Riemser and expands its presence in Europe
1/8/2020
The acquisition provides Esteve with greater pharmaceutical presence in Europe's main markets and a portfolio of proprietary specialty products for hospital use.
-
Acorda to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 9:30am PST / 12:30pm EST.
-
VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study
1/8/2020
VBL Therapeutics (Nasdaq: VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent glioblastoma (rGBM) in two manuscripts published in the peer-reviewed journal Neuro-Oncology, the official journal of the Society for Neuro-Oncology.
-
CV Sciences, Inc. to Participate at the 22nd Annual ICR Conference
1/8/2020
Joseph Dowling, the Company's Chief Executive Officer and Joerg Grasser, Chief Financial Officer, will present and meet with investors at the 22nd Annual ICR Conference in Orlando, Florida being held January 13-15, 2020.
-
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference
-
Righttime Medical Care Earns Antibiotic Stewardship Commendation from Urgent Care Association and College of Urgent Care Medicine
1/8/2020
In order to achieve the Commendation, the UCA and CUCM required Righttime to provide evidence demonstrating a commitment to responsible antibiotic prescribing practices.
-
Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week
1/8/2020
Atriva Therapeutics GmbH, a clinical stage biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announces its participation in three upcoming conferences in San Francisco, CA, USA, in January.
-
Checkmate Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced that it will make a presentation at the 38th Annual J.P. Morgan Healthcare Conference.
-
Promethera® Announces Initiation of Phase 2b DHELIVER Study of HepaStem™ in Patients with Acute-on-Chronic Liver Failure (ACLF)
1/8/2020
Potentially pivotal trial for industry’s most-advanced cell-based therapy in severe liver diseases expected to generate results in H2 2023
-
Helix BioPharma Corp. to Present at the Biotech Showcase Conference in San Francisco
1/8/2020
Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Tuesday, January 14, 2020 at 11:00am (PT) at Hilton San Francisco Union Square.
-
TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer
1/8/2020
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval of SM-88 (racemetyrosine) for the third-line treatment of patients with metastatic pancreatic cancer.